Blue Lotus

'''Blue Lotus''' (''Nymphaea nouchali'' var. ''caerulea'', Nymphaeaceae) — also known as '''Blue Water Lily''' and '''Sacred Blue Lily''' — is an aquatic plant classified as a depressant and [[substance_class:psychoactive/oneirogen]]. Its dominant alkaloid, nuciferine, has a [[glossary:receptor]] profile resembling atypical [[substance_class:psychoactive/antipsychotic|antipsychotics]]{{cite|doi=10.1371/journal.pone.0150602|anchor=bad1c3ad}}. Nuciferine acts on the brain's [[glossary:serotonin]] and [[substance_class:pharmacological/dopamine-system|dopamine systems]], producing [[effect:sedation]] with dream-enhancing qualities. ''N. caerulea'' held sacred status in ancient Egypt for over two thousand years, appearing in tomb art and ritual texts tied to solar symbolism{{cite|pubmed=14749409|anchor=fb63c7ea}}. Archaeochemical analysis confirmed it was used alongside the [[glossary:monoamine-oxidase]]-inhibiting plant ''Peganum harmala'' in ritual preparations as early as the 2nd century BCE{{cite|doi=10.1038/s41598-024-78721-8|anchor=b5b51109}}. Today it is sold openly online across most of the world, with no standardization of content or purity. [[index:effects|Subjective effects]] include mild sedation, gentle [[effect:euphoria]], reduced [[effect:anxiety]], and enhanced dream vividness — the last being the plant's most distinctive quality. Oral tea produces gentle, slow-building relaxation; vaporized resin or concentrated extract brings faster onset and more intense perceptual changes. At higher doses — particularly via inhaled routes — [[effect:confusion]], [[glossary:hallucination|hallucinations]], and [[effect:paranoia]] can occur{{cite|doi=10.1093/milmed/usab328|anchor=2cbc037e}}. No [[glossary:tolerance]], [[glossary:dependence]], or [[glossary:withdrawal]] data have been published for blue lotus{{flag|safety-citation-needed}}. The primary danger is commercial product integrity — [[glossary:synthetic]] [[substance_class:psychoactive/cannabinoid|cannabinoids]] have been documented as [[glossary:adulterant|adulterants]] in vape products{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=190f5400}}, and many commercial products may not contain authentic ''N. caerulea''{{cite|doi=10.3390/molecules28207014|anchor=0992725f}}. Clinical evidence rests on a single [[glossary:case-series]]; the plant has not been studied in controlled human trials{{cite|doi=10.1093/milmed/usab328|anchor=ce7f3a4d}}.

'''Blue Lotus''' (''Nymphaea nouchali'' var. ''caerulea''), also known as '''Blue Water Lily''' and '''Sacred Blue Lily''', is an aquatic perennial in the family Nymphaeaceae, native to the Nile Valley and sub-Saharan Africa. Classified as a depressant and [[substance_class:psychoactive/oneirogen]], its psychoactive profile is attributed primarily to the aporphine alkaloid nuciferine, though published analytical data on authenticated [[glossary:plant-material]] show only trace alkaloid concentrations{{cite|doi=10.3390/molecules28207014|anchor=79cf66fd}}{{flag|claim-unsupported}}. Blue lotus is consumed as tea, tincture, smoked flower, or vaporized resin, with reported total durations of 2–4 hours depending on preparation. First scientifically described by Savigny in 1798 during Napoleon's Egyptian expedition, ''N. caerulea'' held documented ritual significance in ancient Egypt — the plant has been identified archaeochemically in a Ptolemaic-era ritual vessel alongside the [[glossary:monoamine-oxidase]]-inhibiting plant ''Peganum harmala''{{cite|doi=10.1038/s41598-024-78721-8|anchor=9a936c39}}. Despite this cultural record and expanding commercial availability since the 2010s, no controlled human pharmacological study of any ''N. caerulea'' preparation has been published. The plant is [[glossary:unscheduled]] under United States federal law and major international drug treaties, though individual jurisdictions including Louisiana, Russia, and Poland have enacted specific bans. Nuciferine acts as an [[glossary:antagonist]] at [[glossary:5-ht2a]], 5-HT2B, and [[glossary:5-ht2c|5-HT2C receptors]]; an [[glossary:agonist]] at [[glossary:5-ht1a]] and D4 [[glossary:receptor|receptors]]; a [[glossary:partial-agonist]] at D2 and D5; and an [[glossary:inhibitor]] of the [[glossary:dopamine-transporter]] — a profile described as similar to atypical [[substance_class:psychoactive/antipsychotic|antipsychotics]]{{cite|doi=10.1371/journal.pone.0150602|anchor=a3da5731}}. Oral [[glossary:bioavailability]] is approximately 3.8–4.2% in rats; no human pharmacokinetic data have been published{{cite|doi=10.1016/j.jchromb.2014.04.038|anchor=5b5dd1e9}}. The natural occurrence of apomorphine in this plant is chemically contested, with recent analytical work finding it virtually absent from authenticated extracts{{cite|doi=10.3390/molecules28207014|anchor=4d10bb49}}{{flag|claim-unsupported}}. Reported effects include [[effect:sedation]], mild [[effect:euphoria]], [[effect:anxiety-suppression|anxiolysis]], and dose-dependent perceptual [[glossary:disturbance|disturbances]] — the last most pronounced via inhaled preparations. Effects and duration vary substantially by preparation method: vaporized resin produces onset within minutes, while oral tea preparations produce slower onset over 30–60 minutes with longer total duration. The oneirogenic dimension — enhancement of dream vividness and hypnagogic imagery — is consistently reported in community accounts but has not been studied under controlled conditions. No controlled [[glossary:toxicity]] data exist for ''N. caerulea''. A clinical [[glossary:case-series]] documented five patients with sedation and perceptual disturbances after blue lotus use, all recovering with supportive care{{cite|doi=10.1093/milmed/usab328|anchor=c262abec}}. No [[glossary:tolerance]], [[glossary:physical-dependence]], or [[glossary:withdrawal]] data have been published. The principal safety concern is product integrity: commercial products have been documented as laced with [[glossary:synthetic]] [[substance_class:psychoactive/cannabinoid|cannabinoids]]{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=2e9501fd}} and may not contain authentic ''N. caerulea''{{cite|doi=10.3390/molecules28207014|anchor=c8159d6f}}{{flag|claim-unsupported}}. No published dose-response data exist for any preparation.

'''Blue Lotus''' (''Nymphaea nouchali'' var. ''caerulea'', Nymphaeaceae) — also called '''Blue Water Lily''' and '''Sacred Blue Lily''' — is an aquatic perennial classified as a depressant and [[substance_class:psychoactive/oneirogen]]. Its primary psychoactive alkaloid, nuciferine, has a [[glossary:receptor]] profile resembling atypical [[substance_class:psychoactive/antipsychotic|antipsychotics]]{{cite|doi=10.1371/journal.pone.0150602|anchor=7975f745}}. Nuciferine acts through [[glossary:5-ht2a]] [[glossary:antagonism]], D2 partial agonism, and [[glossary:dopamine-transporter]] [[glossary:inhibition]], producing [[effect:sedation]] with oneirogenic qualities. Documented in ancient Egyptian ritual contexts spanning two millennia, ''N. caerulea'' was archaeochemically identified alongside the [[glossary:monoamine-oxidase]]-inhibiting plant ''Peganum harmala'' in a Ptolemaic-era vessel{{cite|doi=10.1038/s41598-024-78721-8|anchor=61d1f8d5}}. Commercial availability expanded substantially in Western markets during the 2010s, though no controlled human pharmacological study has been published. The plant is [[glossary:unscheduled]] under United States federal law and major international treaties, with specific bans in Louisiana, Russia, and Poland. [[index:effects|Subjective effects]] include sedation, mild [[effect:euphoria]], [[effect:anxiety-suppression|anxiolysis]], enhanced dream vividness, and dose-dependent perceptual [[glossary:disturbance|disturbances]]. The experience varies by preparation — vaporized resin produces [[glossary:rapid-onset]] with pronounced perceptual changes, while oral tea yields gentler, longer-lasting sedation. Unwanted effects at higher doses include [[effect:confusion]], [[glossary:hallucination|hallucinations]], and [[effect:paranoia]], particularly via inhaled routes{{cite|doi=10.1093/milmed/usab328|anchor=465db902}}. No [[glossary:tolerance]], [[glossary:dependence]], or [[glossary:withdrawal]] data have been published, and no formal [[glossary:toxicity]] studies exist{{flag|safety-citation-needed}}. The dominant safety concern is product integrity — commercial products have been laced with [[glossary:synthetic]] [[substance_class:psychoactive/cannabinoid|cannabinoids]]{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=d8dd5711}} and may not contain authentic ''N. caerulea''{{cite|doi=10.3390/molecules28207014|anchor=0ff8d885}}. Clinical evidence rests on a single [[glossary:case-series]] and military adverse event reports, with no controlled trials conducted{{cite|doi=10.1093/milmed/usab328|anchor=b2c5dd52}}.

===Ancient Egyptian use=== ''Nymphaea caerulea'' held documented religious and cultural significance in ancient Egypt, appearing in tomb frescoes, papyrus scrolls, temple carvings, and funerary goods spanning more than two millennia. Blue lotus petals were found among funerary goods in the tomb of Tutankhamun (c. 1323 BCE){{flag|citation-needed}}. Depictions of Nymphaea species appear in the Book of the Dead and other ritual texts associated with resurrection and solar symbolism{{cite|pubmed=14749409|anchor=217b155c}}. McDonald traced Egyptian lotus symbolism and ritualistic practices to approximately 2500 BCE, documenting the plant's influence on sacral tree worship throughout the Fertile Crescent{{cite|doi=10.3390/rel9090256|anchor=df0f6cae}}. Tanasi and colleagues conducted a multianalytical investigation of a Ptolemaic-era Bes-vase (c. 2nd century BCE), identifying ''N. nouchali'' var. ''caerulea'' alongside ''Peganum harmala'' (a source of [[glossary:monoamine-oxidase]]-inhibiting harmala alkaloids), a ''Cleome'' genus plant, fermented fruit, honey, and human biological fluids using LC-MS/MS, proteomics, metabolomics, and genetic sequencing{{cite|doi=10.1038/s41598-024-78721-8|anchor=24546d69}}. This finding provides direct archaeochemical evidence that blue lotus was incorporated into complex ritual preparations, potentially alongside [[substance_class:pharmacological/monoamine-oxidase-inhibitor|monoamine oxidase inhibitors]] that could have potentiated its alkaloid effects. The exact pharmacological significance of blue lotus within ancient Egyptian ritual practice — as distinct from its well-established symbolic and ornamental roles — remains an active area of scholarly interpretation, not a settled historical fact. ===Mesoamerican and Mediterranean parallels=== Archaeological evidence from Maya contexts includes ''Nymphaea ampla'' (White Water Lily), with apomorphine-class alkaloids identified in bulbs and roots, suggesting functionally analogous ritual use of Nymphaea species across cultures{{cite|pubmed=14749409|anchor=1167302e}}. Minoan Crete cult scenes have been interpreted by some scholars as involving psychoactive Nymphaea species, though this remains contentious{{cite|doi=10.1080/1751696x.2015.1026029|anchor=205147c6}}. ===Scientific description and Western encounter=== The plant was first scientifically described as ''Nymphaea caerulea'' by Marie Jules César Savigny in 1798 in ''Décade égyptienne'', a periodical of Napoleon Bonaparte's scientific expedition to Egypt{{cite|name=powo-nymphaea-range|type=web|author=Royal Botanic Gardens Kew|year=2024|title=Nymphaea caerulea Plants of the World Online taxonomy notes|anchor=c1efecea}}. The modern accepted binomial ''Nymphaea nouchali'' var. ''caerulea'' was established in subsequent taxonomic revision by Verdcourt. ===Traditional medical use=== In traditional African medicine, ''N. caerulea'' and related Nymphaea species have documented use for analgesic, sedative, anti-inflammatory, and aphrodisiac purposes{{flag|citation-needed}}. The closely related ''Nymphaea lotus'' (White Lotus) demonstrates [[substance_class:psychoactive/anxiolytic]] properties validated in [[glossary:rodent-model|rodent models]]{{cite|pubmed=29881419|anchor=f71691c2}}. No peer-reviewed ethnopharmacological study specifically addressing ''N. caerulea'' traditional medical use in Africa was identified in published literature. ===Modern era=== Commercial availability of blue lotus as a psychoactive herb expanded substantially in Western markets during the 2010s–2020s, driven by online retail. Poklis and colleagues published among the first clinical-context reports in Western medical literature in 2017, analyzing blue lotus resin used in electronic cigarettes{{cite|doi=10.1080/02791072.2017.1290304|anchor=03587fa8}}. No clinical trials studying ''N. caerulea'' in human subjects have been registered on [[glossary:clinicaltrials-gov]]. Published pharmacological research has concentrated on isolated nuciferine — predominantly sourced from ''Nelumbo nucifera'' leaf — investigating its [[substance_class:psychoactive/antipsychotic]]-like properties{{cite|doi=10.1371/journal.pone.0150602|anchor=05f59d31}} and anti-obesity potential{{cite|doi=10.1016/j.phrs.2021.106002|anchor=a0724da7}}{{cite|doi=10.1016/j.phrs.2023.106820|anchor=0d6e6bb7}}, rather than on whole ''N. caerulea'' preparations.

===Ancient Egyptian use=== ''Nymphaea caerulea'' held documented religious significance in ancient Egypt for over two millennia, with roots traced to approximately 2500 BCE{{cite|doi=10.3390/rel9090256|anchor=3bc36a9b}}. Blue lotus appears in the Book of the Dead and funerary goods, including Tutankhamun's tomb (c. 1323 BCE){{cite|pubmed=14749409|anchor=7cdb8df8}}{{flag|citation-needed}}. Archaeochemical analysis of a Ptolemaic-era ritual vessel confirmed it was combined with ''Peganum harmala'' and fermented honey — direct evidence of complex ritual preparations{{cite|doi=10.1038/s41598-024-78721-8|anchor=413bbe12}}. ===Western discovery and modern era=== The plant was first formally described as ''Nymphaea caerulea'' by Savigny in 1798{{cite|name=powo-nymphaea-range|type=web|author=Royal Botanic Gardens Kew|year=2024|title=Nymphaea caerulea Plants of the World Online taxonomy notes|anchor=82766efa}}. Western clinical reporting began in 2017 with cases involving blue lotus resin in electronic cigarettes{{cite|doi=10.1080/02791072.2017.1290304|anchor=f64acbfa}}; pharmacological research since then has focused on isolated nuciferine for [[substance_class:psychoactive/antipsychotic]]-like{{cite|doi=10.1371/journal.pone.0150602|anchor=048dab46}} and anti-obesity properties{{cite|doi=10.1016/j.phrs.2021.106002|anchor=02f1e955}}{{cite|doi=10.1016/j.phrs.2023.106820|anchor=74d9d346}}, not on whole ''N. caerulea'' preparations. No controlled clinical trial studying ''N. caerulea'' in human subjects has been registered. {{DiscoverMore|Cross-Cultural Parallels}} Archaeological evidence from Maya contexts includes ''Nymphaea ampla'' (White Water Lily), with apomorphine-class alkaloids identified in the plant, suggesting analogous ritual use of Nymphaea species across cultures{{cite|pubmed=14749409|anchor=8e0804d3}}. Minoan Crete cult scenes have been interpreted by some scholars as involving psychoactive Nymphaea species, though this remains contested{{cite|doi=10.1080/1751696x.2015.1026029|anchor=95c263e5}}. {{/DiscoverMore}} {{DiscoverMore|Traditional Medical Use}} In traditional African medicine, ''N. caerulea'' and related Nymphaea species have documented use as analgesic, sedative, and aphrodisiac preparations{{flag|citation-needed}}. The closely related ''Nymphaea lotus'' shows [[substance_class:psychoactive/anxiolytic]] properties in [[glossary:animal-model|animal models]]{{cite|pubmed=29881419|anchor=779c4ec6}}. {{/DiscoverMore}}

===Ancient Egyptian use=== ''Nymphaea caerulea'' held documented religious and cultural significance in ancient Egypt, appearing in tomb frescoes, papyrus scrolls, and funerary goods spanning more than two millennia. Blue lotus petals were found among funerary goods in the tomb of Tutankhamun (c. 1323 BCE){{flag|citation-needed}}. Depictions appear in the Book of the Dead and other ritual texts tied to resurrection and solar symbolism{{cite|pubmed=14749409|anchor=9b17eb64}}. McDonald traced Egyptian lotus symbolism to approximately 2500 BCE, documenting the plant's influence on sacral worship throughout the Fertile Crescent{{cite|doi=10.3390/rel9090256|anchor=acbcb78e}}. Tanasi and colleagues identified ''N. nouchali'' var. ''caerulea'' alongside ''Peganum harmala'', fermented fruit, honey, and human biological fluids in a Ptolemaic-era Bes-vase (c. 2nd century BCE){{cite|doi=10.1038/s41598-024-78721-8|anchor=7187eb4e}}. This provides direct archaeochemical evidence that blue lotus was incorporated into complex ritual preparations — potentially alongside [[substance_class:pharmacological/monoamine-oxidase-inhibitor|monoamine oxidase inhibitors]] that could have potentiated its alkaloid effects. The pharmacological significance of blue lotus in Egyptian ritual remains an active area of scholarly interpretation, not a settled historical fact. ===Western discovery and research=== The plant was first scientifically described as ''Nymphaea caerulea'' by Savigny in 1798 in ''Décade égyptienne'', a periodical of Napoleon's expedition to Egypt{{cite|name=powo-nymphaea-range|type=web|author=Royal Botanic Gardens Kew|year=2024|title=Nymphaea caerulea Plants of the World Online taxonomy notes|anchor=7cc405d4}}. The modern accepted binomial ''Nymphaea nouchali'' var. ''caerulea'' was established in subsequent taxonomic revision by Verdcourt. ===Modern era=== Commercial availability expanded in Western markets during the 2010s–2020s, driven by online retail. Poklis and colleagues published among the first clinical-context reports in Western medical literature in 2017, analyzing blue lotus resin used in electronic cigarettes{{cite|doi=10.1080/02791072.2017.1290304|anchor=38d7a30f}}. Published pharmacological research has focused on isolated nuciferine — predominantly sourced from ''Nelumbo nucifera'' — investigating its [[substance_class:psychoactive/antipsychotic]]-like properties{{cite|doi=10.1371/journal.pone.0150602|anchor=1c2a5af7}} and anti-obesity potential{{cite|doi=10.1016/j.phrs.2021.106002|anchor=0de90012}}{{cite|doi=10.1016/j.phrs.2023.106820|anchor=258ec336}}, rather than whole ''N. caerulea'' preparations. No clinical trials studying ''N. caerulea'' in human subjects have been registered. {{DiscoverMore|Cross-Cultural Parallels}} Archaeological evidence from Maya contexts includes ''Nymphaea ampla'' (White Water Lily), with apomorphine-class alkaloids identified in bulbs and roots, suggesting functionally analogous ritual use of Nymphaea species across cultures{{cite|pubmed=14749409|anchor=b7d4707b}}. Minoan Crete cult scenes have been interpreted by some scholars as involving psychoactive Nymphaea species, though this remains contentious{{cite|doi=10.1080/1751696x.2015.1026029|anchor=dc93a3fc}}. {{/DiscoverMore}} {{DiscoverMore|Traditional Medical Use}} In traditional African medicine, ''N. caerulea'' and related Nymphaea species have documented use for analgesic, sedative, anti-inflammatory, and aphrodisiac purposes{{flag|citation-needed}}. The closely related ''Nymphaea lotus'' demonstrates [[substance_class:psychoactive/anxiolytic]] properties validated in [[glossary:rodent-model|rodent models]]{{cite|pubmed=29881419|anchor=5fe66084}}. No peer-reviewed ethnopharmacological study specifically addressing ''N. caerulea'' traditional medical use in Africa was identified. {{/DiscoverMore}}

''Nymphaea nouchali'' var. ''caerulea'' belongs to the family Nymphaeaceae (water lilies). It was first described as ''Nymphaea caerulea'' by Savigny in 1798; the current accepted name reflects a later taxonomic revision placing it within the broader ''N. nouchali'' complex. It is distinct from ''Nymphaea lotus'' (White Lotus) and ''Nelumbo nucifera'' (Sacred Lotus, family Nelumbonaceae) — both frequently confused with it in commercial markets. The plant is native to the Nile Valley and sub-Saharan Africa, growing in freshwater lakes, ponds, and slow-moving rivers{{cite|name=powo-nymphaea-range|type=web|author=Royal Botanic Gardens Kew|year=2024|title=Nymphaea caerulea Plants of the World Online taxonomy notes|anchor=621a8c1d}}. It has been introduced to parts of the Indian subcontinent and Southeast Asia. ''N. caerulea'' is day-blooming — opening in the morning and closing by afternoon — a behaviour linked to its solar symbolism in ancient Egypt{{cite|pubmed=14749409|anchor=a6823b1a}}. The flowers are star-shaped with pointed pale-to-vivid blue petals arranged around a cluster of yellow stamens. Leaves are round, waxy, and float on the water surface with a notch at the base. Unlike ''Nelumbo nucifera'', whose leaves and flowers rise above the water, ''N. caerulea'' floats directly on the surface. Many commercial products labeled as blue lotus do not match authenticated ''N. caerulea'' extracts{{cite|doi=10.3390/molecules28207014|anchor=097ec9d2}}.

The accepted binomial is ''Nymphaea nouchali'' var. ''caerulea'' (Savigny) Verdc., as confirmed by Plants of the World Online and World Flora Online{{cite|name=wfo-nymphaea|type=web|author=World Flora Online|year=2024|title=Nymphaea nouchali var. caerulea - taxonomy distribution synonyms|anchor=b21b7773}}. The widely used name ''Nymphaea caerulea'' Savigny is treated as a synonym but remains prevalent in pharmacological and commercial literature. Historical synonyms include ''N. madagascariensis'' DC., ''N. magnifica'' Gilg, ''N. mildbraedii'' Gilg, ''N. nubica'' Lehm., ''N. spectabilis'' Gilg, ''N. capensis'' Thunb., and ''N. calliantha'' Conard{{cite|name=wfo-nymphaea|type=web|author=World Flora Online|year=2024|title=Nymphaea nouchali var. caerulea - taxonomy distribution synonyms|anchor=90a304f3}}. The genus ''Nymphaea'' comprises approximately 50 species of aquatic perennials distributed globally. Of these, ''N. caerulea'', ''N. lotus'' (White Egyptian Lotus), and ''N. ampla'' (White Water Lily) carry pharmacological significance due to their aporphine alkaloid content. ''N. caerulea'' grows in still or slow-moving freshwater bodies — lakes, rivers, and ponds — across its native range from the Nile Valley through East Africa to South Africa. The plant produces pale blue to lavender flowers approximately 10–15 cm in diameter, borne on long stalks above floating peltate leaves. Flowers are diurnal, opening in the morning and closing by afternoon — a cycle historically associated with solar symbolism in ancient Egypt. Leaves are broadly ovate with smooth margins and a characteristic notch at the petiole insertion. The plant propagates via rhizomes and seeds. Major producing regions for commercial herbal products are not clearly documented in peer-reviewed literature. ===Misidentification risks=== ''N. caerulea'' must not be confused with ''Nelumbo nucifera'' (Sacred Lotus, Pink Lotus), which belongs to a taxonomically distinct family (Nelumbonaceae) but shares nuciferine as a major alkaloid. The two genera are not closely related despite common use of the word "lotus" for both. A more consequential identification concern involves commercial products. Dosoky and colleagues found that eleven commercial products sold as blue lotus did not resemble authenticated ''N. caerulea'' extracts in aroma or chemical composition{{cite|doi=10.3390/molecules28207014|anchor=b29964ec}}. Preliminary research by McEvoy at the UC Berkeley Center for the Science of [[substance_class:psychoactive/psychedelic|Psychedelics]] found evidence that products sold online as "blue lotus" may consist of a different water lily species than authentic ''N. caerulea''{{cite|name=ucb-bluelotus|type=web|author=McEvoy L|year=2024|title=UC Berkeley research on blue lotus identity and commercial products|anchor=108ecf75}}. This product identity risk is significant: consumers purchasing "blue lotus" may receive material with a different and uncharacterized phytochemical profile.

''Nymphaea nouchali'' var. ''caerulea'' belongs to the family Nymphaeaceae (water lilies). The species was originally described as ''Nymphaea caerulea'' by Savigny in 1798; the current accepted name reflects Verdcourt's subsequent revision placing it as a variety of the broader ''N. nouchali'' complex. It is distinct from ''Nymphaea lotus'' (White Lotus, same family) and ''Nelumbo nucifera'' (Sacred Lotus, family Nelumbonaceae) — both of which are frequently confused with it in commercial markets. The plant is native to the Nile Valley and sub-Saharan Africa, where it grows in freshwater lakes, ponds, and slow-moving rivers{{cite|name=powo-nymphaea-range|type=web|author=Royal Botanic Gardens Kew|year=2024|title=Nymphaea caerulea Plants of the World Online taxonomy notes|anchor=5050a556}}. It has been introduced to parts of the Indian subcontinent and Southeast Asia. ''N. caerulea'' is a day-blooming aquatic perennial, opening its flowers in the morning and closing them by afternoon — a behaviour linked to its solar symbolism in ancient Egyptian culture{{cite|pubmed=14749409|anchor=89cf0696}}. Flowers are the primary identification feature: star-shaped with pointed petals in pale to vivid blue, arranged around a central cluster of yellow stamens. Leaves are round, waxy, and float on the water surface with a characteristic notch at the base where the petiole attaches. The plant should not be confused with ''Nelumbo nucifera'', whose leaves and flowers rise above the water surface rather than floating on it. Species verification of commercial products is unreliable — analytical work has found that many products labeled as blue lotus do not match authenticated ''N. caerulea'' extracts{{cite|doi=10.3390/molecules28207014|anchor=ac1dfd5b}}. Flowers and occasionally rhizomes are harvested for psychoactive use, typically dried for tea or further processed into tinctures and concentrated resins.

Nuciferine is the primary psychoactive constituent of ''N. caerulea''. Published analysis of authenticated [[glossary:plant-material]] shows only trace alkaloid concentrations overall{{cite|doi=10.3390/molecules28207014|anchor=094f63a2}}. Nuciferine blocks certain [[glossary:serotonin]] [[glossary:receptor|receptors]], partially activates [[glossary:dopamine]] receptors, and slows the brain's dopamine [[glossary:reuptake]] — a combined profile resembling atypical [[substance_class:psychoactive/antipsychotic]] [[glossary:medication|medications]]{{cite|doi=10.1371/journal.pone.0150602|anchor=c93d5770}}. Apomorphine — a dopamine activator used clinically for Parkinson's disease — was once attributed to ''N. caerulea'', but recent analysis of authenticated extracts found it virtually absent{{cite|doi=10.3390/molecules28207014|anchor=cbc58a9d}}. Even if present, apomorphine is poorly absorbed when swallowed — less than 2% reaches the bloodstream{{cite|doi=10.1016/j.xphs.2020.12.010|anchor=bfd006d0}}. Minor constituents include flavonoids; the related ''Nymphaea lotus'' shows [[substance_class:psychoactive/anxiolytic]] effects in [[glossary:animal-model|animal models]]{{cite|pubmed=29881419|anchor=9b61799e}}, suggesting other bioactive compounds may exist beyond nuciferine. Nuciferine's oral [[glossary:absorption]] is low — roughly 3.8–4.2% in animal studies{{cite|doi=10.1016/j.jchromb.2014.04.038|anchor=04d7cd24}} — and it absorbs poorly under neutral or alkaline conditions{{cite|doi=10.1080/03639045.2018.1483399|anchor=be122c96}}. No human pharmacokinetic data exist. [[glossary:potency]] varies significantly across batches; eleven commercial products tested did not resemble authenticated ''N. caerulea'' extracts in chemical composition{{cite|doi=10.3390/molecules28207014|anchor=74a0245f}}.

===Primary alkaloid: nuciferine=== Nuciferine (C₁₉H₂₁NO₂; MW 295.4) is an aporphine-class alkaloid and the principal psychoactively relevant constituent confirmed in ''N. caerulea''{{cite|doi=10.1371/journal.pone.0150602|anchor=1dd750f3}}. Two peer-reviewed analytical studies reach markedly different conclusions about its concentration in blue lotus products: * Poklis and colleagues detected nuciferine in all five samples analyzed (four commercial products and one confiscated resin). The resin contained 4,300 ng/g nuciferine{{cite|doi=10.1080/02791072.2017.1290304|anchor=61bb19b6}}. * Dosoky and colleagues analyzed six authenticated industrial ''N. caerulea'' extracts (concretes and absolutes) by GC-MS and found nuciferine present only at trace concentrations of 10–72 ppb{{cite|doi=10.3390/molecules28207014|anchor=beada2ea}}. This discrepancy likely reflects differences in extraction methodology, plant parts used, and source material authenticity. Standard aromatic extraction methods (concretes, absolutes) do not concentrate aporphine alkaloids; solvent extraction and concentration of dried flowers or resin appear necessary to produce psychoactively meaningful alkaloid levels. No systematic quantification of nuciferine across cultivars, harvest conditions, or plant parts has been published. ===Apomorphine: contested natural occurrence=== Apomorphine (C₁₇H₁₇NO₂; MW 267.32), a catechol aporphine and well-characterized [[glossary:dopamine]] [[glossary:agonist]] used clinically in Parkinson's disease, has been historically attributed to ''N. caerulea''. Poklis and colleagues detected apomorphine in two of five commercial samples{{cite|doi=10.1080/02791072.2017.1290304|anchor=7ea4c676}}, while Dosoky and colleagues found it virtually absent from authenticated extracts, noting that its natural occurrence in the plant "is doubtful on chemical grounds"{{cite|doi=10.3390/molecules28207014|anchor=af724857}}. Apomorphine detected in commercial products may reflect [[glossary:adulterant|adulteration]], a processing artifact, or [[glossary:misidentification]] of the plant species. Any pharmacological attribution to [[glossary:endogenous]] apomorphine in ''N. caerulea'' must be treated as unresolved. ===Non-alkaloid phytochemistry=== Agnihotri and colleagues isolated 20 constituents from ''N. caerulea'' flowers — no aporphine alkaloids were detected in this study{{cite|doi=10.1016/j.phytochem.2008.04.009|anchor=67274e51}}. Identified compounds included flavonoid glycosides (myricetin 3-O-rhamnoside, quercetin 3-O-rhamnoside, quercetin 3-O-glucoside, kaempferol and naringenin glycosides, isosalipurposide), phenolic acids (gallic acid, ethyl gallate, p-coumaric acid, 4-methoxybenzoic acid), and phytosterols (β-sitosterol and [[glossary:derivative|derivatives]]). Nine compounds demonstrated [[substance_class:pharmacological/antioxidant]] activity. Dosoky and colleagues characterized authenticated extracts as consisting primarily of aliphatic hydrocarbons, aromatic [[substance:alcohol|alcohols]], fatty acids, phenyl derivatives, diterpenoids, and phytosterols{{cite|doi=10.3390/molecules28207014|anchor=18fea5f1}}. In the related ''Nelumbo nucifera'', additional aporphine-class alkaloids have been identified including pronuciferine, nornuciferine, armepavine, and asimilobine{{cite|doi=10.1211/jpp.61.04.0001|anchor=3a29bfcc}}{{cite|doi=10.1155/2015/789124|anchor=6ee8adb2}}. He and colleagues identified 48 compounds including 26 alkaloids from ''N. nucifera'' leaves, petals, and seeds — with nuciferine, armepavine, asimilobine, and luteolin as key sleep-relevant components{{cite|doi=10.1002/cbdv.202402788|anchor=564b1c95}}. Whether these additional aporphine alkaloids co-occur in ''N. caerulea'' has not been established by published analytical studies. ===Preparation effects on alkaloid content=== No peer-reviewed study directly compares nuciferine concentrations across ''N. caerulea'' preparation methods (tea, tincture, smoked flower, extracted resin). The contrast between near-absent alkaloids in authenticated aromatic extracts{{cite|doi=10.3390/molecules28207014|anchor=b526c10e}} and measurable nuciferine in concentrated resin{{cite|doi=10.1080/02791072.2017.1290304|anchor=37bb0af8}} indicates that processing method substantially determines psychoactive alkaloid availability. [[glossary:potency]] varies across commercial products, and no standardized alkaloid content requirement or mandatory testing program exists for blue lotus preparations.

Nuciferine, an aporphine alkaloid, is considered the primary psychoactive constituent of ''N. caerulea''. Published analytical data on authenticated [[glossary:plant-material]] show only trace alkaloid concentrations overall{{cite|doi=10.3390/molecules28207014|anchor=66392362}}. Nuciferine acts as an [[glossary:antagonist]] at [[glossary:serotonin]] [[glossary:5-ht2a|5-HT2A receptors]], a [[glossary:partial-agonist]] at [[glossary:d2-receptor|dopamine D2 receptors]], and an [[glossary:inhibitor]] of the [[glossary:dopamine-transporter]] — a combined profile described as resembling atypical [[substance_class:psychoactive/antipsychotic|antipsychotics]]{{cite|doi=10.1371/journal.pone.0150602|anchor=b80e78e7}}. The natural occurrence of apomorphine in ''N. caerulea'' is chemically contested. Early analyses attributed some of the plant's effects to apomorphine, a non-selective [[glossary:dopamine]] [[glossary:agonist]] used clinically for Parkinson's disease. Recent analytical work on authenticated extracts found apomorphine virtually absent{{cite|doi=10.3390/molecules28207014|anchor=7bb4bd2f}}. Even if present, apomorphine's oral [[glossary:bioavailability]] is less than 2% due to extensive [[glossary:first-pass-metabolism|first-pass]] [[glossary:metabolism|hepatic metabolism]]{{cite|doi=10.1016/j.xphs.2020.12.010|anchor=d5440c80}}, rendering oral preparations an ineffective delivery route for systemic apomorphine exposure. Minor constituents include flavonoids, phytosterols, and uncharacterized alkaloids whose contribution to the psychoactive profile remains unknown. The closely related ''Nymphaea lotus'' demonstrates [[substance_class:psychoactive/anxiolytic]] properties in [[glossary:rodent-model|rodent models]]{{cite|pubmed=29881419|anchor=e917c4c6}}, suggesting the broader Nymphaea alkaloid milieu may contain bioactive compounds beyond nuciferine, though none have been individually characterized for ''N. caerulea''. [[glossary:potency]] varies significantly across cultivars, harvest conditions, and commercial preparations. Dosoky and colleagues found that eleven commercial products did not resemble authenticated ''N. caerulea'' extracts in chemical composition{{cite|doi=10.3390/molecules28207014|anchor=7f16a7dc}}, underscoring both natural variability and the risk of species substitution in the commercial supply chain. Oral bioavailability of nuciferine is approximately 3.8–4.2% in rats{{cite|doi=10.1016/j.jchromb.2014.04.038|anchor=fe89ae8b}}. Nuciferine shows pH-dependent oral [[glossary:absorption]], classified as well-soluble under acidic conditions but poorly absorbed under neutral or alkaline conditions{{cite|doi=10.1080/03639045.2018.1483399|anchor=6f8113f1}}. No human pharmacokinetic data have been published, and the low oral bioavailability raises unresolved questions about what effective alkaloid concentrations reach the [[glossary:central-nervous-system]] via tea or tincture preparations.

===Where it acts=== Nuciferine acts on the brain's [[glossary:serotonin]] and [[substance_class:pharmacological/dopamine-system|dopamine systems]]. Blocking certain serotonin [[glossary:receptor|receptors]] reduces perceptual distortion risk; partially activating [[glossary:dopamine]] receptors and slowing dopamine [[glossary:reuptake]] contributes to mild mood lift and [[effect:sedation]]{{cite|doi=10.1371/journal.pone.0150602|anchor=0ff3afe8}}. In [[glossary:animal-model|animal models]], nuciferine resembled clozapine — an atypical [[substance_class:psychoactive/antipsychotic]] — in behavioral tests, without producing the muscle stiffness caused by older antipsychotics{{cite|doi=10.1371/journal.pone.0150602|anchor=2af73b64}}. ===What it changes=== The brain's calming [[substance_class:pharmacological/gaba-system]] may also contribute: extract from the related ''Nymphaea lotus'' extended sleep duration in mice in a way consistent with [[glossary:gaba]] receptor involvement{{cite|pubmed=29881419|anchor=e85325fc}}. Nuciferine reaches the brain after administration, confirming it crosses the [[glossary:blood-brain-barrier]]{{cite|doi=10.1016/j.jchromb.2014.04.038|anchor=ed33ea66}}. Related lotus plants inhibit [[glossary:liver-enzymes]] that process certain [[glossary:medication|medications]]{{cite|doi=10.1016/j.jep.2014.02.014|anchor=21c45755}}, suggesting blue lotus may alter how co-administered drugs are metabolized. {{DiscoverMore|Open Questions}} No neuroimaging studies with ''N. caerulea'' have been published. Key unsolved questions include what nuciferine concentrations are achieved by human oral and inhaled preparations, whether animal [[glossary:bioavailability]] data translate to humans, and whether plant constituents beyond nuciferine contribute meaningfully to the experience{{cite|name=mitra-2022-nelumbo|type=web|author=Mitra K et al.|year=2022|title=Therapeutic Potential of Nelumbo nucifera in CNS Disorders|anchor=11732110}}. {{/DiscoverMore}}

===Where it acts=== Nuciferine's combined [[glossary:5-ht2a]] [[glossary:antagonism]], [[glossary:5-ht1a]] agonism, D2 partial agonism, and [[glossary:dopamine-transporter]] [[glossary:inhibition]] collectively account for the sedative, [[substance_class:psychoactive/anxiolytic]], and mild perceptual effects reported with blue lotus{{cite|doi=10.1371/journal.pone.0150602|anchor=94d178b9}}. The 5-HT1A agonism is associated with [[effect:anxiety-suppression|anxiolysis]], while D2 partial agonism contributes to [[effect:sedation]]. In [[glossary:rodent-model|rodent]] behavioural models, nuciferine blocked 5-HT2A [[glossary:agonist]]-induced [[glossary:head-twitch-response|head-twitch responses]], substituted for clozapine in [[glossary:discriminative-stimulus|drug discrimination]], and rescued [[substance:pcp]]-induced prepulse inhibition [[glossary:disruption]] — without producing catalepsy{{cite|doi=10.1371/journal.pone.0150602|anchor=8a8e1e23}}. ===What it changes=== The GABAergic system may also contribute: ''Nymphaea lotus'' extract potentiated [[substance:pentobarbital]]-induced sleep in mice{{cite|pubmed=29881419|anchor=bc228400}}, consistent with [[glossary:gaba-a-receptor]] involvement, though this has not been directly tested for nuciferine or ''N. caerulea'' preparations. Nuciferine distributes to brain, liver, and adipose tissue after administration, confirming [[glossary:central-nervous-system]] penetration{{cite|doi=10.1016/j.jchromb.2014.04.038|anchor=f97b2036}}. [[glossary:cyp2d6]] inhibition has been identified [[glossary:in-vitro|in vitro]] for related ''Nelumbo nucifera'' extracts{{cite|doi=10.1016/j.jep.2014.02.014|anchor=9f918b1b}}, raising the possibility of altered [[glossary:metabolism]] of co-administered drugs. {{DiscoverMore|Open Questions}} No neuroimaging studies with ''N. caerulea'' have been published. Key unresolved questions include: (1) what nuciferine [[glossary:plasma-concentration|plasma concentrations]] are achieved by human oral and inhaled preparations; (2) whether the low oral [[glossary:bioavailability]] (~4%) observed in rats translates to humans; and (3) whether constituents other than nuciferine contribute meaningfully to the psychoactive profile through unknown [[glossary:receptor-binding|receptor interactions]]{{cite|name=mitra-2022-nelumbo|type=web|author=Mitra K et al.|year=2022|title=Therapeutic Potential of Nelumbo nucifera in CNS Disorders|anchor=9e53c4d9}}. {{/DiscoverMore}}

Blue lotus produces a characteristically gentle sedative-oneirogenic experience. At lower doses, oral preparations bring mild relaxation, reduced [[effect:anxiety]], and quiet well-being. At higher doses or via inhaled routes, the experience shifts toward perceptual changes and vivid hypnagogic imagery — the dream-like quality the plant is best known for. This dimension is strongest in pre-sleep contexts and varies substantially with [[glossary:set-and-setting]]. The experience occupies a distinct niche. Nuciferine's [[glossary:receptor]] profile is closer to an atypical [[substance_class:psychoactive/antipsychotic]] than to a classical sedative or [[substance_class:chemical/benzodiazepine]], yet at typical doses the character more closely resembles a mild [[substance_class:psychoactive/anxiolytic]] tea with dream-enhancing [[glossary:aftereffect|aftereffects]]. Vaporized preparations differ meaningfully from oral ones — faster onset, a higher [[glossary:intensity]] ceiling, and less predictable effects. Because commercial products frequently lack authentic [[glossary:plant-material]], actual experiences may not reflect what genuine ''N. caerulea'' pharmacology predicts.

Blue lotus produces a characteristically gentle sedative-oneirogenic experience. At lower doses, oral preparations yield mild relaxation, [[effect:anxiety-suppression|anxiolysis]], and a sense of well-being; at higher doses or via inhaled routes, perceptual shifts and vivid hypnagogic imagery emerge. The oneirogenic quality — enhanced dream vividness and liminal-state imagery — is the defining experiential signature, most consistently reported in pre-sleep contexts. [[glossary:set-and-setting]] modulate this dimension substantially, and preparation method determines both onset speed and [[glossary:intensity]] ceiling. The experience occupies a pharmacological niche distinct from classical sedative-[[substance_class:psychoactive/hypnotic|hypnotics]]. Nuciferine's [[glossary:receptor]] profile positions it closer to atypical [[substance_class:psychoactive/antipsychotic|antipsychotics]] than to [[substance_class:chemical/benzodiazepine|benzodiazepines]], yet at typical doses the subjective character more closely resembles a mild [[substance_class:psychoactive/anxiolytic]] tea with dream-enhancing [[glossary:aftereffect|aftereffects]] than any clinical antipsychotic experience. The significant product [[glossary:adulterant|adulteration]] risk means that the actual experience of any given commercial product may not reflect the pharmacology of authentic ''N. caerulea''.

{{Warning}}No peer-reviewed [[glossary:controlled-study|controlled human study]] establishing dose-response for any ''N. caerulea'' preparation has been identified. All dose values below derive from commercial packaging, non-peer-reviewed sources, and community reports. These values are '''unverified against published research''' and must not be treated as established clinical data. See the Dose by preparation card for structured reference.{{/Warning}} ===Tea=== Dried ''N. caerulea'' flowers steeped in hot water (approximately 80–90°C). Commonly reported preparation uses 3–10 g of dried flower material steeped for 10–20 minutes{{flag|safety-citation-needed}}. Onset is reported at 30–60 minutes, with total subjective duration of 2–4 hours{{flag|safety-citation-needed}}. Tea represents the historically documented oral preparation, consistent with infused beverage use in ancient Egyptian contexts{{cite|pubmed=14749409|anchor=744d3a99}}. One patient in the Schimpf [[glossary:case-series]] presented after consuming a blue lotus infused beverage{{cite|doi=10.1093/milmed/usab328|anchor=893929ef}}. The low oral [[glossary:bioavailability]] of nuciferine observed in rats (~4%){{cite|doi=10.1016/j.jchromb.2014.04.038|anchor=e9df4b04}} and the pH-dependent [[glossary:absorption]] profile favoring acidic conditions{{cite|doi=10.1080/03639045.2018.1483399|anchor=973063fd}} suggest that gastric pH may influence alkaloid [[glossary:reuptake|uptake]] from tea preparations, though this has not been tested in humans. ===Infused wine=== Flowers soaked in wine, sometimes with oil infusion to facilitate alkaloid release into lipophilic solvent. This preparation is documented archaeologically: the Ptolemaic Bes-vase analyzed by Tanasi and colleagues contained evidence of ''N. caerulea'' alongside fermented fruit{{cite|doi=10.1038/s41598-024-78721-8|anchor=4600b383}}. No published data quantify alkaloid yield or bioavailability for wine-infused preparations. The [[substance:alcohol]] solvent may improve extraction efficiency relative to aqueous tea{{flag|citation-needed}}, and ethanol co-administration would bypass some [[glossary:first-pass-metabolism|first-pass]] metabolic limitations of nuciferine. ===Tincture=== Alcohol-extracted concentrate, typically administered [[glossary:sublingual|sublingually]]. Non-peer-reviewed sources report doses of 5–15 drops with onset at 15–30 minutes{{flag|safety-citation-needed}}. Sublingual administration bypasses first-pass [[glossary:metabolism|hepatic metabolism]], which is relevant given nuciferine's poor oral bioavailability in rats{{cite|doi=10.1016/j.jchromb.2014.04.038|anchor=37f3ec22}}. No published analytical data quantify nuciferine content in commercial blue lotus tinctures. ===Smoked flower=== Dried ''N. caerulea'' flower material smoked via combustion. Onset reported within 5–15 minutes via non-peer-reviewed sources{{flag|safety-citation-needed}}. No published data characterize dose-response, alkaloid delivery efficiency, or combustion byproducts for smoked blue lotus flower. Pulmonary administration bypasses first-pass metabolism and delivers alkaloids directly to pulmonary vasculature for rapid systemic distribution. ===Vaporized resin or extract=== Blue lotus resin or concentrated extract vaporized using electronic cigarette devices, including rebuildable dripping atomizers. Poklis and colleagues analyzed a confiscated resin aerosolized via this method, detecting 4,300 ng/g nuciferine{{cite|doi=10.1080/02791072.2017.1290304|anchor=f7695bf1}}. Four of five patients in the Schimpf case series presented after vaping blue lotus resin or extract, experiencing [[effect:sedation]] and perceptual [[glossary:disturbance|disturbances]]{{cite|doi=10.1093/milmed/usab328|anchor=e033ea25}}. Onset via vaporization is the most rapid of all preparations. This route produced the most pronounced clinical effects documented in published [[glossary:case-report|case reports]]. No peer-reviewed data compare alkaloid concentrations, bioavailability, or effect profiles systematically across these preparation methods. The contrast between near-absent nuciferine in authenticated aromatic extracts and measurable nuciferine in concentrated resin indicates that preparation method is the primary determinant of psychoactive alkaloid availability.

No published dose-response data exist for any ''N. caerulea'' preparation. All [[glossary:dose-range|dose ranges]] below derive from community reports and are not clinically validated. [[glossary:potency]] varies substantially between products and batches. * '''Tea''' (dried flowers steeped 10–20 minutes in hot water): community-reported amounts of 2–5 g of dried flower material per cup. Onset 30–60 minutes; total duration 2–4 hours. Produces mild [[effect:sedation]], gentle [[effect:euphoria]], and [[effect:anxiety-suppression|anxiolysis]]. Avoids combustion byproducts associated with smoking. * '''Smoked flower''' (dried petals in a pipe or rolled preparation): onset within minutes; total duration 1–2 hours. Produces more pronounced perceptual effects than oral routes{{cite|doi=10.1093/milmed/usab328|anchor=ad79751f}}. Combustion introduces respiratory irritants not present with other preparations. * '''Vaporized resin or extract''' (electronic cigarettes or vaporizers): fastest onset, within minutes; most intense effects{{cite|doi=10.1080/02791072.2017.1290304|anchor=07175aa1}}. Perceptual [[glossary:disturbance|disturbances]] and altered mental status are more likely than with oral preparations{{cite|doi=10.1093/milmed/usab328|anchor=213ff8ef}}. Carries the highest [[glossary:adulterant]] risk — [[glossary:synthetic]] [[substance_class:psychoactive/cannabinoid]] lacing is specifically documented in vaporized blue lotus products{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=1a59db3c}}. * '''Tincture''' ([[substance:alcohol]] extraction of dried flower material): onset 30–60 minutes; duration 2–4 hours. Offers more consistent dosing than raw flower but remains unstandardized. No regulatory body enforces alkaloid content labeling. * '''Infused wine''' (flowers steeped in wine): a historically documented preparation with at least one case in the published clinical literature{{cite|doi=10.1093/milmed/usab328|anchor=2c01cd2a}}. Alcohol adds its own sedative pharmacology and may alter alkaloid [[glossary:absorption]]. Onset and [[glossary:intensity]] differ significantly between preparations — vaporized products act within minutes while oral preparations take 30–60 minutes to reach full effect. Per-preparation dose tiers and timeline data are in the Dose · by preparation card on this page.

No published dose-response data exist for any ''N. caerulea'' preparation. All [[glossary:dose-range|dose ranges]] below derive from community reports and are not clinically validated. [[glossary:potency]] varies substantially between products and batches — start low and titrate cautiously. ====Tea (oral)==== '''Tea''' is the most traditional preparation. Dried flowers or petals are steeped in hot water for 10–20 minutes. Onset is gradual, typically 30–60 minutes, with total duration of 2–4 hours. The experience is characterized by mild [[effect:sedation]], gentle [[effect:euphoria]], and [[effect:anxiety-suppression|anxiolysis]]. Community-reported amounts range from 2–5 g of dried flower material per cup, though potency varies substantially between products. Tea preparation avoids combustion byproducts associated with smoking. ====Smoked flower==== '''Smoked flower''' involves smoking dried petals in a pipe or rolled preparation. Onset is rapid, typically within minutes, with total duration of 1–2 hours. Inhaled preparations produce more pronounced perceptual effects and altered mental status compared to oral routes{{cite|doi=10.1093/milmed/usab328|anchor=049034e5}}. Combustion introduces respiratory irritant risks not present with other preparations. ====Vaporized resin or extract==== '''Vaporized resin''' or concentrated extract, used in electronic cigarettes or vaporizers, produces the most rapid and intense effects{{cite|doi=10.1080/02791072.2017.1290304|anchor=1cc9cbb7}}. Onset occurs within minutes, with perceptual [[glossary:disturbance|disturbances]] and altered mental status more likely than with oral preparations{{cite|doi=10.1093/milmed/usab328|anchor=ff2a47c0}}. Concentrated products carry the highest [[glossary:adulterant]] risk — [[glossary:synthetic]] [[substance_class:psychoactive/cannabinoid]] lacing has been specifically documented in vaporized blue lotus products{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=37d61279}}. Dosing is particularly unreliable due to variable extraction concentrations and absent standardization. ====Tincture (oral)==== '''Tincture''' preparations involve [[substance:alcohol]] extraction of dried flower material. Onset and duration are similar to tea (30–60 minutes onset, 2–4 hours total). Tinctures offer more consistent dosing than raw flower material but remain unstandardized. No regulatory body enforces alkaloid content labeling for blue lotus tinctures. ====Infused wine==== '''Infused wine''' — steeping flowers in wine — has historical precedent in ancient practice and remains a preparation method. Alcohol may alter [[glossary:absorption]] kinetics and adds its own sedative pharmacology. One clinical case in the published literature involved an infused beverage{{cite|doi=10.1093/milmed/usab328|anchor=8bc40937}}. Per-preparation dose tiers, timelines, and [[glossary:bioavailability]] data are in the Dose · by preparation card on this page.

====Toxicity==== No [[glossary:lethal-dose|LD50]] or formal [[glossary:acute-toxicity]] data exist for ''N. caerulea'' or its preparations{{flag|safety-citation-needed}}. The only published clinical evidence is a single [[glossary:case-series]]: five military patients developed altered mental status after blue lotus use — four after vaping and one after an infused beverage — all recovering with supportive care and no fatalities{{cite|doi=10.1093/milmed/usab328|anchor=fd713b66}}. DoD adverse event data additionally document [[glossary:hallucination|hallucinations]], [[effect:paranoia]], slurred speech, [[glossary:chest-pain]], [[glossary:tachycardia|rapid heartbeat]], and [[glossary:seizure]] following blue lotus use{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=f10fa165}}. No fatalities attributed to ''N. caerulea'' alone have been identified in published literature. '''Contaminant and adulterant risk''' is the most significant safety concern for commercial blue lotus products. '''Synthetic cannabinoid lacing:''' Blue lotus [[glossary:plant-material]] has been laced with [[glossary:synthetic]] [[substance_class:psychoactive/cannabinoid|cannabinoids]] — controlled substances capable of causing seizure, cardiovascular collapse, and [[glossary:psychosis]]{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=49c6c693}}. '''Species misidentification:''' Eleven commercial products tested did not resemble authenticated ''N. caerulea'' extracts in chemical composition{{cite|doi=10.3390/molecules28207014|anchor=ec129138}}. Independent research suggests many online products may consist of a different water lily species{{cite|name=ucb-bluelotus|type=web|author=McEvoy L|year=2024|title=UC Berkeley research on blue lotus identity and commercial products|anchor=365d174e}}. '''No standardization:''' No regulatory body approves blue lotus for [[glossary:human-consumption]]. Standard [[glossary:reagent-kit|reagent kits]] (Marquis, Mandelin) are not validated for blue lotus alkaloids. [[substance:fentanyl]] test strips cannot detect synthetic cannabinoids. Laboratory LC-MS/MS or GC-MS analysis is required to confirm species identity and screen for [[glossary:adulterant|adulterants]]. Blue lotus alkaloids do not appear on standard urine drug screens{{cite|doi=10.1093/milmed/usab328|anchor=2aaa378d}}. Products laced with synthetic cannabinoids may [[glossary:trigger]] positive results. ====Psychological Risks==== High doses and inhaled preparations can produce [[effect:confusion]], hallucinations, and paranoia{{cite|doi=10.1093/milmed/usab328|anchor=c0feb19d}}{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=394cf6fc}}. No published data address precipitation of [[glossary:psychotic-episodes]] in vulnerable individuals. Nuciferine's [[glossary:receptor]] profile theoretically suggests lower psychosis risk than [[glossary:serotonergic-psychedelics|classical psychedelics]]{{cite|doi=10.1371/journal.pone.0150602|anchor=028600e7}}, but this [[glossary:inference]] cannot be extended to adulterated commercial products. ====Tolerance & Dependence==== No published data exist on [[glossary:tolerance]] development, [[glossary:physical-dependence]], or [[glossary:withdrawal]] from ''N. caerulea'' or nuciferine in humans{{flag|safety-citation-needed}}. Nuciferine's partial action on [[glossary:dopamine]] receptors raises a theoretical possibility of tolerance with repeated use, analogous to patterns with other dopamine [[glossary:partial-agonist|partial agonists]], but this has not been studied. No [[glossary:case-report|case reports]] of blue lotus [[glossary:dependence]] or withdrawal have been published. Absence of data does not indicate absence of risk. ====Drug Interactions==== Related lotus plants inhibit [[glossary:liver-enzymes]] — including [[glossary:cyp2d6]], [[glossary:cyp2c9]], [[glossary:cyp2c19]], and [[glossary:cyp3a4]] — that process many common [[glossary:medication|medications]]{{cite|doi=10.1016/j.jep.2014.02.014|anchor=7c0f8c6a}}. Drugs processed by these [[glossary:enzyme|enzymes]] ([[substance:codeine]], [[substance:tramadol]], certain [[substance_class:psychoactive/antidepressant|antidepressants]], [[substance_class:psychoactive/antipsychotic|antipsychotics]], beta-[[glossary:blocker|blockers]]) could accumulate at higher concentrations. The following interactions are mechanistically plausible but lack clinical documentation: * '''Antipsychotics:''' Nuciferine acts on the same dopamine and [[glossary:serotonin]] receptors as antipsychotics; the combination could augment or disrupt antipsychotic dosing. * '''Serotonergic antidepressants (SSRIs, SNRIs):''' Nuciferine's dopamine and serotonin activity raises theoretical concern in combination. * '''MAO inhibitors (including ''Peganum harmala''):''' Historically combined in ritual preparations{{cite|doi=10.1038/s41598-024-78721-8|anchor=8f20ab69}}. MAOIs could amplify the [[glossary:monoamine]]-related effects of blue lotus alkaloids{{flag|safety-citation-needed}}. * '''CNS depressants (alcohol, benzodiazepines, opioids):''' Additive [[effect:sedation]] is expected given nuciferine's sedative properties. All interactions listed are mechanistically plausible but unsupported by clinical case reports or formal pharmacokinetic studies. ====Contraindications==== * '''Pregnancy and lactation:''' No published safety data exist. Use should be avoided{{flag|safety-citation-needed}}. * '''Psychiatric conditions:''' Dopamine and serotonin receptor activity makes use in psychotic [[glossary:disorder|disorders]], bipolar disorder, or during psychotropic medication use a concern requiring caution. * '''Cardiovascular disease:''' Chest pain and tachycardia documented in adverse event reports{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=5e32e073}}. * '''Seizure disorders:''' At least one seizure documented in adverse event reports; whether intrinsic to the plant or from adulteration is unknown{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=a008345e}}. * '''Hepatic impairment:''' Potential [[glossary:cytochrome-p450|CYP enzyme]] [[glossary:inhibition]] may alter drug [[glossary:metabolism]]{{flag|safety-citation-needed}}. * '''Military service:''' Blue lotus is prohibited for all U.S. service members including off-duty use per the DoD Prohibited Dietary Supplement Ingredients List{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=b835fffc}}.

====Toxicity==== No [[glossary:lethal-dose|LD50]] or formal [[glossary:acute-toxicity]] data exist for ''N. caerulea'' or its preparations in any species{{flag|safety-citation-needed}}. Clinical evidence is limited to a single [[glossary:case-series]]: Schimpf and colleagues documented five military patients presenting with altered mental status after blue lotus use — four after vaping resin or extract and one after consuming an infused beverage{{cite|doi=10.1093/milmed/usab328|anchor=626bb3e4}}. All recovered with supportive care alone; no fatalities were documented. Department of Defense adverse event data additionally document [[glossary:hallucination|hallucinations]], [[effect:euphoria]], [[effect:paranoia]], [[effect:anxiety]], slurred speech, decreased responsiveness, chest pain, [[glossary:tachycardia|rapid heartbeat]], and [[glossary:seizure]] following blue lotus use{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=1a22ae20}}. Chest pain and tachycardia suggest cardiovascular involvement, though the mechanism is unclear and may reflect adulteration. No fatalities attributed to ''N. caerulea'' alone have been identified in published literature. '''Contaminant and adulterant risk''' constitutes the most significant safety concern for blue lotus products. '''Synthetic cannabinoid lacing:''' Blue lotus plant material has been commonly laced with [[glossary:synthetic]] [[substance_class:psychoactive/cannabinoid|cannabinoids]] — potent controlled substances that can produce seizure, cardiovascular collapse, and [[glossary:psychosis]]{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=43deaad2}}. '''Species misidentification:''' Eleven commercial products tested did not resemble authenticated ''N. caerulea'' extracts in chemical composition or aroma{{cite|doi=10.3390/molecules28207014|anchor=29ee1d61}}. UC Berkeley research corroborates this finding, suggesting online products may consist of a different water lily species{{cite|name=ucb-bluelotus|type=web|author=McEvoy L|year=2024|title=UC Berkeley research on blue lotus identity and commercial products|anchor=58944cc0}}. '''No standardization:''' No regulatory body approves blue lotus for human consumption. No standardized alkaloid content requirements, GMP enforcement, or mandatory testing programs exist. Standard [[glossary:reagent-kit|reagent test kits]] (Marquis, Mandelin) are not validated for blue lotus alkaloids. [[substance:fentanyl]] test strips do not detect synthetic cannabinoids. Laboratory LC-MS/MS or GC-MS analysis is required to confirm species identity and alkaloid content. Blue lotus alkaloids (nuciferine, apomorphine) are not detectable on standard 5-, 10-, or 12-panel urine drug screens{{cite|doi=10.1093/milmed/usab328|anchor=38b30d8c}}. Products adulterated with synthetic cannabinoids may [[glossary:trigger]] positive results. ====Psychological Risks==== Dose-dependent perceptual [[glossary:disturbance|disturbances]], hallucinations, and [[effect:confusion]] have been documented at high doses or via inhaled preparations{{cite|doi=10.1093/milmed/usab328|anchor=9b52db20}}. Paranoia and anxiety are documented in military clinical reports{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=2cf2f76e}}. Vaporized resin and extract produced more pronounced altered mental status than [[glossary:ingestion|oral ingestion]] in the available case series. No published data address precipitation of [[glossary:psychotic-episodes]] in individuals with pre-existing [[glossary:vulnerability]]. Nuciferine's [[glossary:5-ht2a]] [[glossary:antagonism]] theoretically suggests low psychotomimetic risk relative to 5-HT2A [[glossary:agonist|agonists]]{{cite|doi=10.1371/journal.pone.0150602|anchor=e34e67f5}}, but this [[glossary:inference]] cannot be generalized to uncharacterized commercial preparations that may contain synthetic adulterants. Chronic [[glossary:psychological-risk|psychological risks]] of repeated blue lotus use have not been studied. ====Tolerance & Dependence==== No published data on [[glossary:tolerance]] development, physical dependence, or [[glossary:withdrawal]] from ''N. caerulea'' or nuciferine in humans exist{{flag|safety-citation-needed}}. Nuciferine's partial D2 agonism suggests theoretical dopaminergic tolerance may develop with repeated use, analogous to patterns seen with other D2 partial agonists, but this has not been investigated. No [[glossary:case-report|case reports]] of blue lotus [[glossary:dependence]] or withdrawal have been published. Absence of data does not indicate absence of risk. ====Drug Interactions==== '''CYP enzyme inhibition:''' ''Nelumbo nucifera'' leaf extract — which shares nuciferine with ''N. caerulea'' — contains potent [[glossary:in-vitro|in vitro]] [[glossary:cyp2d6]] [[glossary:inhibitor|inhibitors]], along with inhibitory activity on CYP2C9, [[glossary:cyp2c19]], CYP2E1, and [[glossary:cyp3a4]]{{cite|doi=10.1016/j.jep.2014.02.014|anchor=83d0655f}}. No human [[glossary:pharmacokinetic-interaction]] studies exist, and clinical significance at typical blue lotus doses is unknown. CYP2D6-metabolized drugs include [[substance:codeine]], [[substance:tramadol]], [[substance_class:psychoactive/antidepressant|antidepressants]] (fluoxetine, paroxetine, venlafaxine), [[substance_class:psychoactive/antipsychotic|antipsychotics]] (haloperidol, risperidone), and beta-[[glossary:blocker|blockers]] (metoprolol). Co-administration with substantial blue lotus intake could theoretically elevate [[glossary:plasma-concentration|plasma concentrations]] of these [[glossary:medication|medications]], though this represents in vitro extrapolation from a related species, not a documented clinical interaction. '''Pharmacodynamic interactions:''' * '''Antipsychotics:''' [[glossary:potentiation|Synergy]] or antagonism at D2 and 5-HT2A receptors. Nuciferine may augment or complicate antipsychotic dosing. * '''Serotonergic antidepressants (SSRIs, SNRIs):''' [[glossary:dopamine-transporter]] [[glossary:inhibition]] combined with [[glossary:serotonin]] [[glossary:receptor]] activity raises theoretical concern, though no clinical cases have been reported. * '''MAO inhibitors (including ''Peganum harmala''):''' Historical [[glossary:polydrug|co-use]] documented archaeochemically{{cite|doi=10.1038/s41598-024-78721-8|anchor=bcef9332}}. MAOI co-administration could potentiate monoaminergic effects of blue lotus alkaloids{{flag|safety-citation-needed}}. * '''CNS depressants (alcohol, benzodiazepines, opioids):''' Additive [[effect:sedation]] expected given nuciferine's sedative properties. All interactions listed are mechanistically plausible but unsupported by clinical case reports or formal pharmacokinetic studies. ====Contraindications==== * '''Pregnancy and lactation:''' No published safety data exist. Use should be avoided{{flag|safety-citation-needed}}. * '''Psychiatric conditions:''' Given pharmacodynamic interactions with [[glossary:dopamine]] and serotonin receptor systems, use in individuals with psychotic [[glossary:disorder|disorders]], bipolar disorder, or those taking psychotropic medications requires caution. * '''Cardiovascular disease:''' Chest pain and tachycardia documented in adverse event reports{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=7df7e643}}. * '''Seizure disorders:''' At least one seizure documented in adverse event reports{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=6a07cb13}}. Whether this reflects intrinsic pharmacology or adulteration is unknown. * '''Hepatic impairment:''' Given potential [[glossary:cytochrome-p450|CYP enzyme]] inhibition and [[glossary:metabolism|hepatic metabolism]] of nuciferine, altered drug metabolism may result{{flag|safety-citation-needed}}. * '''Military service:''' Blue lotus is prohibited for all U.S. service members including off-duty use per the DoD Prohibited Dietary Supplement Ingredients List{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=f4fa70c6}}.

===Forms & Identification=== Blue lotus enters the market as dried flowers, pre-rolled blends, tinctures, concentrated resins, and vape cartridges. None of these carry verified alkaloid content labeling. Laboratory testing (LC-MS/MS or GC-MS) is the only reliable method to confirm species identity, alkaloid content, and absence of [[glossary:synthetic]] [[glossary:adulterant|adulterants]] — standard [[glossary:reagent-kit|reagent kits]] and [[substance:fentanyl]] test strips cannot detect blue lotus alkaloids or synthetic [[substance_class:psychoactive/cannabinoid]] [[glossary:contamination|contaminants]]. Purchase from vendors who provide a Certificate of Analysis from an ISO-accredited laboratory. If a product produces effects inconsistent with mild [[effect:sedation]] — particularly [[glossary:rapid-onset|rapid-onset]] intense [[effect:euphoria]], strong dissociation, or acute [[effect:anxiety]] — discontinue use immediately, as synthetic cannabinoid adulteration is a documented risk. ===Set & Setting=== Blue lotus is best suited to calm, low-demand environments. The oneirogenic effects are most pronounced in pre-sleep settings. Avoid operating vehicles or machinery after use. If using an inhaled preparation for the first time, have a sober companion present — vaporized products produce more rapid and less predictable effects than oral preparations. Avoid combining with [[substance:alcohol]], which adds unpredictable sedation. ===Guidelines=== {{Guideline}} * Start with the lowest commonly reported dose for the preparation chosen. For tea, begin with 1–2 g of dried flower; for vaporized products, take a single small inhalation and wait 10 minutes before [[glossary:redose|redosing]]. * Use only one preparation method per session. Do not combine oral and inhaled routes. * Do not use blue lotus products of unknown provenance. Products without third-party lab testing carry documented synthetic cannabinoid adulteration risk. * If using for sleep or dream enhancement, consume 1–2 hours before intended sleep time and do not redose. * Allow at least several days between uses until your individual response pattern is established. {{/Guideline}} ===Emergency Response=== {{Emergency}} '''Recognizing an emergency:''' * Severe [[effect:confusion]] or unresponsiveness * [[glossary:chest-pain]] or [[glossary:tachycardia|rapid heartbeat]] * [[glossary:seizure]] activity * Intense [[effect:paranoia]], panic, or [[glossary:psychosis|psychotic symptoms]] * Breathing difficulty '''Immediate steps:''' * '''1.''' Do not leave the person alone. * '''2.''' If the person is unconscious or seizing, place them in the [[glossary:recovery-position]]. * '''3.''' Call emergency services (911 in the US, 112 in the EU, 999 in the UK) if symptoms include seizure, chest pain, [[glossary:loss-of-consciousness]], or breathing difficulty. * '''4.''' Do not attempt to induce [[effect:vomiting]]. * '''5.''' Remove any vaporizer or smoking material from the area. '''What to tell the dispatcher:''' * That the person consumed a blue lotus product (specify preparation: vape, tea, resin, etc.) * Approximate amount and time of consumption * Current symptoms * Whether any other substances were consumed * [[glossary:good-samaritan-law|Good Samaritan laws]] exist in many jurisdictions — calling for help should not result in legal consequences for drug use. '''Reversal agents:''' No specific reversal agent exists for blue lotus. If synthetic cannabinoid adulteration is suspected, treatment is supportive. [[substance_class:chemical/benzodiazepine|Benzodiazepines]] may be administered by medical professionals for seizures. {{/Emergency}} ===Aftercare & Integration=== {{Aftercare}} Post-experience grogginess or residual sedation is common, particularly after higher doses or evening use. Hydrate and eat a light meal after the experience ends. If the experience produced anxiety or [[effect:dysphoria]], recognize that effects are self-limiting and typically resolve within 2–4 hours of onset. Avoid redosing to counteract unwanted effects. If vivid dreams or disrupted sleep patterns persist beyond 24 hours after a single use, allow several days without use before reassessing. {{/Aftercare}} ===Recovery & Support=== {{Recovery}} No formal [[glossary:dependence]] or [[glossary:withdrawal]] has been documented for blue lotus, but habitual use of any psychoactive substance warrants self-assessment. If blue lotus use has become daily or near-daily, or if you find it difficult to sleep without it, consider tapering by reducing frequency before stopping entirely. For general [[glossary:substance-use]] concerns: * '''SAMHSA National Helpline:''' 1-800-662-4357 (free, confidential, 24/7) * '''SAMHSA online treatment locator:''' https://findtreatment.gov * '''Crisis Text Line:''' Text HOME to 741741 If a blue lotus product was adulterated with synthetic cannabinoids and you experience ongoing symptoms after use, seek medical evaluation. {{/Recovery}}

===Forms & Identification=== Blue lotus enters the market as dried flowers, pre-rolled blends, tinctures, concentrated resins, and vape cartridges. None carry verified alkaloid content labeling. Standard [[glossary:reagent-kit|reagent test kits]] and [[substance:fentanyl]] test strips cannot detect blue lotus alkaloids or [[glossary:synthetic]] [[substance_class:psychoactive/cannabinoid]] [[glossary:contamination|contaminants]]. Laboratory LC-MS/MS or GC-MS testing is the only reliable method to confirm species identity and screen for [[glossary:adulterant|adulterants]]. Purchase only from vendors who provide a Certificate of Analysis from an ISO-accredited laboratory. If a product produces effects inconsistent with mild [[effect:sedation]] — especially [[glossary:rapid-onset|rapid-onset]] intense [[effect:euphoria]], strong dissociation, or acute [[effect:anxiety]] — discontinue use immediately. Synthetic cannabinoid contamination is a documented risk. ===Set & Setting=== Blue lotus suits calm, low-demand environments. The oneirogenic effects are most pronounced in pre-sleep settings. Do not operate vehicles or machinery after use. For a first experience with any inhaled preparation, have a sober companion present — vaporized products are faster and less predictable than oral ones. Avoid combining with [[substance:alcohol]], which adds unpredictable sedation. ===Guidelines=== {{Guideline}} * Start with the lowest commonly reported dose for the preparation chosen. For tea, begin with 1–2 g of dried flower; for vaporized products, take a single small inhalation and wait 10 minutes before considering [[glossary:redose|redosing]]. * Use only one preparation method per session. Do not combine oral and inhaled routes. * Do not use products of unknown provenance. Products without third-party lab testing carry documented synthetic cannabinoid adulteration risk. * For sleep or dream enhancement, consume 1–2 hours before intended sleep and do not redose. * Allow at least several days between uses until individual response is established. {{/Guideline}} ===Emergency Response=== {{Emergency}} '''Recognizing an emergency:''' * Severe [[effect:confusion]] or unresponsiveness * [[glossary:chest-pain]] or [[glossary:tachycardia|rapid heartbeat]] * [[glossary:seizure]] activity * Intense [[effect:paranoia]], panic, or [[glossary:psychosis|psychotic symptoms]] * Breathing difficulty '''Immediate steps:''' * '''1.''' Do not leave the person alone. * '''2.''' If unconscious or seizing, place in the [[glossary:recovery-position]]. * '''3.''' Call emergency services (911 in the US, 112 in the EU, 999 in the UK) if symptoms include seizure, chest pain, [[glossary:loss-of-consciousness]], or breathing difficulty. * '''4.''' Do not attempt to induce [[effect:vomiting]]. * '''5.''' Remove any vaporizer or smoking material from the area. '''What to tell the dispatcher:''' * That the person consumed a blue lotus product (specify preparation: vape, tea, resin, etc.) * Approximate amount and time of consumption * Current symptoms * Whether any other substances were consumed * [[glossary:good-samaritan-law|Good Samaritan laws]] exist in many jurisdictions — calling for help should not result in legal consequences for drug use. '''Reversal agents:''' No specific reversal agent exists for blue lotus. If synthetic cannabinoid adulteration is suspected, treatment is supportive. [[substance_class:chemical/benzodiazepine|Benzodiazepines]] may be administered by medical professionals for seizures. {{/Emergency}} ===Aftercare & Integration=== {{Aftercare}} Post-experience grogginess or residual sedation is common, particularly after higher doses or evening use. Hydrate and eat a light meal after effects resolve. If the experience produced anxiety or [[effect:dysphoria]], effects are self-limiting and typically resolve within 2–4 hours of onset. Do not redose to counteract unwanted effects. If vivid dreams or disrupted sleep persist beyond 24 hours after a single use, allow several days without use before reassessing. {{/Aftercare}} ===Recovery & Support=== {{Recovery}} No formal [[glossary:dependence]] or [[glossary:withdrawal]] has been documented for blue lotus, but habitual use of any psychoactive substance warrants self-assessment. If blue lotus use has become daily or near-daily, or if sleep without it has become difficult, consider reducing frequency before stopping entirely. For general [[glossary:substance-use]] concerns: * '''SAMHSA National Helpline:''' 1-800-662-4357 (free, confidential, 24/7) * '''SAMHSA online treatment locator:''' https://findtreatment.gov * '''Crisis Text Line:''' Text HOME to 741741 If a blue lotus product was adulterated with synthetic cannabinoids and symptoms persist after use, seek medical evaluation. {{/Recovery}}

===Nuciferine receptor profile=== Farrell and colleagues characterized nuciferine's [[glossary:receptor-binding]] profile through the NIMH Psychoactive Drug Screening Program{{cite|doi=10.1371/journal.pone.0150602|anchor=ddc339d0}}:

Receptor target	Action
5-HT2A	Antagonist
5-HT2B	Antagonist
5-HT2C	Antagonist
5-HT7	Inverse agonist
5-HT1A	Agonist
5-HT6	Partial agonist
D2	Partial agonist
D4	Agonist
D5	Partial agonist
Dopamine transporter (DAT)	Inhibitor

This combined profile is described as similar but not identical to aripiprazole and other atypical [[substance_class:psychoactive/antipsychotic|antipsychotics]]. In [[glossary:rodent-model|rodent]] behavioral models, nuciferine blocked [[substance_class:pharmacological/serotonin-2a-receptor-agonist|serotonin 2A receptor agonist]]-induced [[glossary:head-twitch-response|head-twitch responses]], substituted for clozapine in [[glossary:discriminative-stimulus|drug discrimination]], inhibited [[substance:pcp]]-induced locomotion, and rescued PCP-induced prepulse [[glossary:inhibition]] [[glossary:disruption]] — without producing catalepsy{{cite|doi=10.1371/journal.pone.0150602|anchor=64b77c99}}. ===CNS mechanism=== Nuciferine's combined [[glossary:5-ht2a]] [[glossary:antagonism]], [[glossary:5-ht1a]] agonism (associated with [[effect:anxiety-suppression|anxiolysis]]), D2 partial agonism (associated with [[effect:sedation]] and antipsychotic-like effects), and [[glossary:dopamine-transporter]] inhibition collectively account for the reported sedative, [[substance_class:psychoactive/anxiolytic]], and mild perceptual effects of blue lotus preparations. The GABAergic system may also contribute: ''Nymphaea lotus'' extract potentiated [[substance:pentobarbital]]-induced sleep in mice{{cite|pubmed=29881419|anchor=832a5cf0}}, consistent with [[glossary:gaba-a-receptor]] [[glossary:potentiation]], though this mechanism has not been directly tested for nuciferine or ''N. caerulea'' preparations. Mitra and colleagues surveyed [[glossary:central-nervous-system|CNS]] pharmacology of ''Nelumbo nucifera'' alkaloids and identified [[substance_class:psychoactive/antidepressant]], sedative-[[substance_class:psychoactive/hypnotic]], anxiolytic, analgesic-potentiating, anticonvulsant, antipsychotic, and memory-enhancing activities mediated via 5-HT2A receptor [[glossary:blockade]], GABAergic mechanisms, and cAMP [[glossary:modulation]]{{cite|name=mitra-2022-nelumbo|type=web|author=Mitra K et al.|year=2022|title=Therapeutic Potential of Nelumbo nucifera in CNS Disorders|anchor=127e0d71}}. These findings derive from ''Nelumbo nucifera'' and are extrapolated to ''N. caerulea'' based on shared nuciferine content. If apomorphine is genuinely present in [[glossary:ingestion|ingested]] preparations — which remains chemically contested — it would act as a non-selective [[glossary:dopamine]] [[glossary:agonist]] at D1 and [[glossary:d2-receptor|D2 receptors]], with well-characterized pharmacology from clinical use in Parkinson's disease. However, apomorphine's oral [[glossary:bioavailability]] is less than 2% due to extensive [[glossary:first-pass-metabolism|first-pass]] [[glossary:metabolism|hepatic metabolism]]{{cite|doi=10.1016/j.xphs.2020.12.010|anchor=66d17058}}, rendering oral preparations an ineffective delivery route for systemic apomorphine exposure. ===Pharmacokinetics=== All available pharmacokinetic data for nuciferine derive from rat models. No human pharmacokinetic data for nuciferine via any route have been published. Oral bioavailability of nuciferine is approximately 3.8–4.2% in rats (tested at 2.0, 5.0, and 10.0 mg/kg oral doses versus 0.2 mg/kg IV), with one-compartmental [[glossary:pharmacokinetics]] characterized by rapid distribution, extensive tissue [[glossary:reuptake|uptake]], and poor systemic [[glossary:absorption]]{{cite|doi=10.1016/j.jchromb.2014.04.038|anchor=8da5249b}}. Nuciferine distributes to brain, liver, and adipose tissue after IV administration, confirming [[glossary:brain-penetration|CNS penetration]]{{cite|doi=10.1016/j.jchromb.2014.04.038|anchor=8a667674}}. Nuciferine is classified as BCS Class I (good [[glossary:solubility]] and [[glossary:permeability]]) under acidic conditions but BCS Class IV under neutral or alkaline conditions, indicating pH-dependent oral absorption{{cite|doi=10.1080/03639045.2018.1483399|anchor=eafcacbe}}. Wang and colleagues further characterized [[glossary:excretion]] pathways via LC-MS/MS in rats{{cite|doi=10.1080/03639045.2018.1483399|anchor=c99be4d7}}. The low rat oral bioavailability (~4%) raises questions about what effective alkaloid concentrations reach the central nervous system via oral preparations (tea, tincture) in humans. No human tmax, [[glossary:half-life]], or cmax values for nuciferine have been published. ===CYP enzyme involvement=== Ye and colleagues identified potent [[glossary:cyp2d6]] [[glossary:inhibitor|inhibitors]] in ''Nelumbo nucifera'' leaf extract [[glossary:in-vitro|in vitro]], along with inhibitory activity on [[glossary:cyp2c9]], [[glossary:cyp2c19]], CYP2E1, and [[glossary:cyp3a4]]{{cite|doi=10.1016/j.jep.2014.02.014|anchor=7bcb5d47}}. Given shared nuciferine content between ''N. nucifera'' and ''N. caerulea'', CYP2D6 inhibition is a plausible interaction concern for blue lotus products, though this has not been directly tested for ''N. caerulea'' extracts. ===Open questions=== No neuroimaging studies with ''N. caerulea'' or its preparations have been published. Three preparation-specific questions remain unresolved: (1) what nuciferine [[glossary:plasma-concentration|plasma concentrations]] are achieved by different human oral and inhaled preparations; (2) whether the low oral bioavailability observed in rats translates to humans, and whether it is sufficient to produce reported psychoactive effects; and (3) whether constituents other than nuciferine — including flavonoids, phytosterols, or uncharacterized minor alkaloids — contribute meaningfully to the psychoactive profile through unknown receptor interactions or pharmacokinetic modulation.

''Nymphaea caerulea'' is [[glossary:unscheduled|not scheduled]] under any major international drug treaty — the 1961, 1971, or 1988 UN Conventions — and neither nuciferine nor apomorphine is [[glossary:international-control|internationally controlled]]{{cite|name=erowid-lotus-legal|type=web|author=Erowid.org|year=2016|title=Erowid Lotus Legal Status|anchor=089ee612}}. Under U.S. federal law it is unscheduled, but the [[glossary:fda]] has not approved it for [[glossary:human-consumption]] and it cannot legally be marketed as a dietary supplement{{cite|name=erowid-lotus-legal|type=web|author=Erowid.org|year=2016|title=Erowid Lotus Legal Status|anchor=2cb39344}}. Louisiana has banned it for human consumption since 2005{{cite|name=erowid-lotus-legal|type=web|author=Erowid.org|year=2016|title=Erowid Lotus Legal Status|anchor=9ace6077}}, and U.S. military personnel are prohibited from using it on or off duty{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=c0aa964a}}. Russia and Poland both scheduled it in 2009, and Latvia classifies it as a controlled substance{{cite|name=lotus-extracts-legal|type=web|author=Lotus-Extracts.com|year=2024|title=International legal status of blue lotus|anchor=35e6950f}}. The UK{{flag|citation-needed}}, Canada{{flag|citation-needed}}, Germany{{flag|citation-needed}}, Netherlands{{flag|citation-needed}}, and Australia{{cite|name=erowid-lotus-legal|type=web|author=Erowid.org|year=2016|title=Erowid Lotus Legal Status|anchor=93ea9b66}} currently permit it, though regulatory details vary. The principal legal risk for consumers in unregulated markets is [[glossary:synthetic]] [[substance_class:psychoactive/cannabinoid]] [[glossary:adulterant|adulterants]], which are controlled substances in most jurisdictions and can result in criminal [[glossary:liability]] regardless of the plant's own legal status. The complete jurisdiction-by-jurisdiction table is available in the full-tier article. {{Warning}} Legal status changes frequently. This overview reflects status as of the article's last update and is not legal advice. Verify current law in the relevant jurisdiction before acting on this information. {{/Warning}}

''Nymphaea caerulea'' is [[glossary:unscheduled|not scheduled]] under the 1961 Single Convention on Narcotic Drugs, the 1971 [[glossary:convention-on-psychotropic-substances]], or the 1988 UN Convention Against Illicit Traffic. Neither nuciferine nor apomorphine is internationally scheduled{{cite|name=erowid-lotus-legal|type=web|author=Erowid.org|year=2016|title=Erowid Lotus Legal Status|anchor=fb8ccd2b}}. Most jurisdictions permit sale and [[glossary:possession]], while a small number have enacted specific bans. The principal legal risk for consumers in unregulated markets is the presence of [[glossary:synthetic]] [[substance_class:psychoactive/cannabinoid]] [[glossary:adulterant|adulterants]], which are controlled substances in most jurisdictions and can result in criminal [[glossary:liability]] regardless of the plant's own legal status.

Jurisdiction	Status	Notes
United States (federal)	Unscheduled	Not a controlled substance under the Controlled Substances Act. Not FDA-approved for human consumption; cannot be legally marketed as a dietary supplement or food ingredient{{cite|name=erowid-lotus-legal|type=web|author=Erowid.org|year=2016|title=Erowid Lotus Legal Status|anchor=bd5854e7}}
Louisiana (US)	Banned for human consumption	Prohibited since 2005 under Act No. 159, which banned 40 plants including ''N. caerulea'' when intended for human consumption. Exempt for aesthetic, landscaping, or decorative purposes{{cite|name=erowid-lotus-legal|type=web|author=Erowid.org|year=2016|title=Erowid Lotus Legal Status|anchor=91be67ec}}
US Military	Prohibited	Banned for all service members including off-duty use per the DoD Prohibited Dietary Supplement Ingredients List{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=454e8df5}}
Russia	Banned	Scheduled since April 2009 under Federal Law on Narcotic Drugs, alongside ''Salvia divinorum'' and ''Argyreia nervosa''{{cite|name=lotus-extracts-legal|type=web|author=Lotus-Extracts.com|year=2024|title=International legal status of blue lotus|anchor=bebad8c9}}
Poland	Banned	Scheduled since March 2009{{cite|name=lotus-extracts-legal|type=web|author=Lotus-Extracts.com|year=2024|title=International legal status of blue lotus|anchor=c96dda8d}}
Latvia	Banned	Controlled substance{{cite|name=lotus-extracts-legal|type=web|author=Lotus-Extracts.com|year=2024|title=International legal status of blue lotus|anchor=2b21bc0f}}
United Kingdom	Uncertain	Not specifically named in the Misuse of Drugs Act 1971. May fall under the Psychoactive Substances Act 2016 if sold for human consumption; personal possession generally considered legal{{flag|citation-needed}}
Canada	Legal	Not classified as a controlled substance. Legal for sale and possession; therapeutic claims require licensing{{flag|citation-needed}}
Germany	Legal	Permitted under general herbal product regulations{{flag|citation-needed}}
Netherlands	Legal	Available in smart shops; not scheduled{{flag|citation-needed}}
Australia	Legal (uncontrolled)	Not a controlled substance. Not TGA-approved for human consumption or therapeutic use. Typically marketed for aromatic or ceremonial purposes{{cite|name=erowid-lotus-legal|type=web|author=Erowid.org|year=2016|title=Erowid Lotus Legal Status|anchor=b782012d}}

Apomorphine circulates as a regulated prescription pharmaceutical in jurisdictions where it is approved for Parkinson's disease and erectile dysfunction, but this regulatory status pertains to the manufactured drug product, not to [[glossary:plant-material]] containing trace quantities. The plant's alkaloids are not controlled under any international drug treaty.

Blue lotus preparations produce a characteristically sedative-oneirogenic experience whose qualitative character depends strongly on preparation method and — critically — product authenticity. Vaporized resin or extract produces rapid, more pronounced effects including perceptual [[glossary:disturbance|disturbances]] and altered mental status, while oral preparations (tea, infused wine) yield gentler [[effect:sedation]] with reported [[substance_class:psychoactive/anxiolytic]] and mildly euphoric qualities. [[glossary:set-and-setting]] modulate the oneirogenic dimension; dream-enhancing properties are most consistently reported in pre-sleep contexts. The significant product [[glossary:adulterant|adulteration]] risk means that the actual experience of any given commercial product may not reflect the pharmacology of authentic ''N. caerulea''. Blue lotus occupies a pharmacological niche distinct from classical sedative-[[substance_class:psychoactive/hypnotic|hypnotics]]. Nuciferine's [[glossary:receptor]] profile — combining [[glossary:5-ht2a]] [[glossary:antagonism]] with D2 partial agonism and [[glossary:dopamine-transporter]] [[glossary:inhibition]] — positions it closer to atypical [[substance_class:psychoactive/antipsychotic|antipsychotics]] than to [[substance_class:chemical/benzodiazepine|benzodiazepines]] or antihistamines, though at commonly reported doses the [[glossary:subjective-experience]] more closely resembles a mild sedative-anxiolytic with oneirogenic qualities than a clinical antipsychotic effect.

===Toxicity=== No [[glossary:lethal-dose|LD50]] or formal [[glossary:acute-toxicity]] data for ''N. caerulea'' or its preparations exist in any species{{flag|safety-citation-needed}}. Acute toxicity assessment relies entirely on a single published [[glossary:case-series]] and military adverse event reports. Schimpf and colleagues documented five active-duty military patients presenting to the emergency department with altered mental status after blue lotus use: four after vaping resin or extract and one after consuming an infused beverage{{cite|doi=10.1093/milmed/usab328|anchor=cbfaee71}}{{flag|additional-citations-needed}}. Common presentation included [[effect:sedation]] and perceptual [[glossary:disturbance|disturbances]]. All five patients were managed with supportive measures alone without need for sedating agents, and no fatalities were documented. Department of Defense adverse event data additionally document [[glossary:hallucination|hallucinations]], [[effect:euphoria]], [[effect:paranoia]], [[effect:anxiety]], slurred speech, decreased responsiveness, bizarre behavior, chest pain, [[glossary:tachycardia|rapid heartbeat]], and [[glossary:seizure]] in military personnel following blue lotus use{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=b3a32243}}{{flag|additional-citations-needed}}. Chest pain and tachycardia suggest cardiovascular involvement, though the mechanism is unclear and may reflect adulteration rather than intrinsic plant pharmacology. No fatalities attributed to ''N. caerulea'' alone have been identified in published literature. ====Contaminant and adulterant risk==== Commercial blue lotus products carry documented contamination and adulteration risks that constitute the most significant safety concern for this substance. '''Synthetic cannabinoid lacing:''' Department of Defense reports document that blue lotus plant material has been commonly laced with synthetic [[substance_class:psychoactive/cannabinoid|cannabinoids]] — potent, potentially dangerous controlled substances that can produce severe [[glossary:adverse-effects]] including seizure, cardiovascular collapse, and [[glossary:psychosis]], and that [[glossary:trigger]] positive results on standard drug tests{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=6554f5ca}}{{flag|additional-citations-needed}}. '''Species misidentification and substitution:''' Dosoky and colleagues found that eleven commercial products did not resemble authenticated ''N. caerulea'' extracts in chemical composition or aroma{{cite|doi=10.3390/molecules28207014|anchor=4472e2f4}}. Preliminary UC Berkeley research corroborates this finding, suggesting online products labeled as blue lotus may consist of a different water lily species{{cite|name=ucb-bluelotus|type=web|author=McEvoy L|year=2024|title=UC Berkeley research on blue lotus identity and commercial products|anchor=3f6bd89c}}. '''Standardization absent:''' No regulatory body approves blue lotus products for human consumption. No standardized alkaloid content requirements, Good Manufacturing Practice enforcement, or mandatory Certificate of Analysis testing programs exist for this product class. Standard [[glossary:reagent-kit|reagent test kits]] (Marquis, Mandelin) are not validated for blue lotus alkaloids. [[substance:fentanyl]] test strips do not detect synthetic cannabinoids. Laboratory LC-MS/MS or GC-MS analysis is required to confirm species identity and alkaloid content. Blue lotus alkaloids (nuciferine, apomorphine) are not detectable on standard 5-, 10-, or 12-panel urine drug screens{{cite|doi=10.1093/milmed/usab328|anchor=03c6ee6b}}{{flag|additional-citations-needed}}. Products adulterated with synthetic cannabinoids may trigger positive results. ===Psychological risks=== Dose-dependent perceptual disturbances, hallucinations, and [[effect:confusion]] have been documented at high doses or via inhaled preparations{{cite|doi=10.1093/milmed/usab328|anchor=e0588107}}. Paranoia and anxiety are documented in Department of Defense clinical reports{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=56d81942}}. The vaporized resin and extract route produced more pronounced altered mental status than [[glossary:ingestion|oral ingestion]] in the available case series. No published data address precipitation of [[glossary:psychotic-episodes]] in individuals with pre-existing [[glossary:vulnerability]]. Nuciferine's [[glossary:5-ht2a]] [[glossary:antagonism]] theoretically suggests low psychotomimetic risk relative to 5-HT2A [[glossary:agonist|agonists]]{{cite|doi=10.1371/journal.pone.0150602|anchor=e8f62c7a}}{{flag|additional-citations-needed}}, but this [[glossary:inference]] applies to isolated nuciferine under controlled conditions and cannot be generalized to uncharacterized commercial preparations that may contain synthetic adulterants. Chronic [[glossary:psychological-risk|psychological risks]] of repeated blue lotus use have not been studied. ===Tolerance and dependence=== No published data on [[glossary:tolerance]] development, physical dependence, or [[glossary:withdrawal]] from ''N. caerulea'' or nuciferine in humans exist{{flag|safety-citation-needed}}. Nuciferine's partial D2 agonism suggests theoretical dopaminergic tolerance may develop with repeated use, analogous to tolerance patterns observed with other D2 partial agonists, but this has not been investigated. No [[glossary:case-report|case reports]] of blue lotus [[glossary:dependence]] or withdrawal have been published. Absence of data does not indicate absence of risk. ===Drug interactions=== ====CYP enzyme inhibition==== ''Nelumbo nucifera'' leaf extract — which shares nuciferine with ''N. caerulea'' — contains potent [[glossary:in-vitro|in vitro]] [[glossary:cyp2d6]] [[glossary:inhibitor|inhibitors]], along with inhibitory activity on CYP2C9, CYP2C19, CYP2E1, and [[glossary:cyp3a4]]{{cite|doi=10.1016/j.jep.2014.02.014|anchor=450c2dd4}}{{flag|additional-citations-needed}}. No human pharmacokinetic interaction studies exist, and clinical significance at typical blue lotus doses is unknown. Drugs metabolized by CYP2D6 include [[substance:codeine]], [[substance:tramadol]], many [[substance_class:psychoactive/antidepressant|antidepressants]] (fluoxetine, paroxetine, venlafaxine), [[substance_class:psychoactive/antipsychotic|antipsychotics]] (haloperidol, risperidone), and beta-[[glossary:blocker|blockers]] (metoprolol). Co-administration with substantial blue lotus intake could theoretically elevate [[glossary:plasma-concentration|plasma concentrations]] of these [[glossary:medication|medications]], but this represents mechanism-based extrapolation from in vitro data on a related plant species, not a documented clinical interaction. ====Pharmacodynamic interactions==== Nuciferine's complex [[glossary:receptor]] profile creates theoretical pharmacodynamic interactions with multiple drug classes: * '''Antipsychotics:''' Pharmacodynamic [[glossary:potentiation|synergy]] or antagonism at D2 and 5-HT2A receptors. Nuciferine may augment or complicate antipsychotic dosing. * '''Serotonergic antidepressants (SSRIs, SNRIs):''' [[glossary:dopamine-transporter]] [[glossary:inhibition]] combined with [[glossary:serotonin]] receptor activity raises theoretical concern, though no clinical cases have been reported. * '''MAO inhibitors (including natural products such as ''Peganum harmala''):''' The Ptolemaic ritual vase study documented historical [[glossary:polydrug|co-use]] with ''P. harmala''{{cite|doi=10.1038/s41598-024-78721-8|anchor=4ea3bba6}}{{flag|additional-citations-needed}}. MAOI co-administration could potentiate monoaminergic effects of blue lotus alkaloids. No modern clinical case reports of MAOI–blue lotus interaction exist{{flag|safety-citation-needed}}. * '''CNS depressants (alcohol, benzodiazepines, opioids):''' Additive sedation expected given nuciferine's sedative properties. All interactions listed are mechanistically plausible based on nuciferine's pharmacological profile but unsupported by clinical case reports or formal pharmacokinetic studies. Interaction [[glossary:severity]] cannot be stated without clinical data. ===Contraindications=== * '''Pregnancy and lactation:''' No published safety data exist. Use should be avoided{{flag|safety-citation-needed}}. * '''Psychiatric conditions:''' Given pharmacodynamic interactions with [[glossary:dopamine]] and serotonin receptor systems, use in individuals with psychotic [[glossary:disorder|disorders]], bipolar disorder, or those taking psychotropic medications requires caution. No published data quantify this risk specifically for blue lotus. * '''Cardiovascular disease:''' Chest pain and tachycardia documented in adverse event reports{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=cbb46d67}}. Mechanism unclear; cardiac monitoring warranted in clinical presentations. * '''Seizure disorders:''' At least one seizure documented in adverse event reports{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=7bba3f14}}. Whether this reflects intrinsic plant pharmacology or adulteration is unknown. * '''Hepatic impairment:''' Given potential [[glossary:cytochrome-p450|CYP enzyme]] inhibition and [[glossary:metabolism|hepatic metabolism]] of nuciferine, individuals with [[glossary:hepatic-impairment|impaired hepatic function]] may experience altered drug metabolism{{flag|safety-citation-needed}}. * '''Military service:''' Blue lotus is prohibited for all U.S. service members including off-duty use per the Department of Defense Prohibited Dietary Supplement Ingredients List{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=f74bfed8}}.

''Nymphaea caerulea'' is [[glossary:unscheduled|not scheduled]] under the 1961 Single Convention on Narcotic Drugs, the 1971 [[glossary:convention-on-psychotropic-substances]], or the 1988 UN Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. Neither nuciferine nor apomorphine is internationally scheduled as a controlled substance{{cite|name=erowid-lotus-legal|type=web|author=Erowid.org|year=2016|title=Erowid Lotus Legal Status|anchor=03b79a79}}. Legal status is fragmented across jurisdictions, with most countries permitting sale and [[glossary:possession]] while a small number have enacted specific bans. Apomorphine is used as a prescription pharmaceutical for Parkinson's disease and erectile dysfunction but is not scheduled as a controlled substance.

Jurisdiction	Classification	Key provisions
United States (federal)	Unscheduled	Not listed as a controlled substance under the Controlled Substances Act. Not approved by the FDA for human consumption; cannot be legally marketed as a dietary supplement or food ingredient{{cite|name=erowid-lotus-legal|type=web|author=Erowid.org|year=2016|title=Erowid Lotus Legal Status|anchor=338e3c6f}}
Louisiana (US)	Banned for human consumption	Prohibited since August 8, 2005 under Louisiana Act No. 159, which banned 40 plants including ''N. caerulea'' when intended for human consumption. Exemption for aesthetic, landscaping, or decorative purposes{{cite|name=erowid-lotus-legal|type=web|author=Erowid.org|year=2016|title=Erowid Lotus Legal Status|anchor=d09ae0e5}}
US Military	Prohibited	Banned for all service members including off-duty use per the DoD Prohibited Dietary Supplement Ingredients List{{cite|name=dod-opss-bluelotus|type=web|author=Operation Supplement Safety (OPSS)|year=2024|title=DoD Prohibited Dietary Supplement Ingredients Blue Lotus|anchor=de9b70e2}}
Russia	Banned	Scheduled since April 2009 under Federal Law on Narcotic Drugs and Psychotropic Substances, alongside Spice products, ''Salvia divinorum'', and ''Argyreia nervosa''{{cite|name=lotus-extracts-legal|type=web|author=Lotus-Extracts.com|year=2024|title=International legal status of blue lotus|anchor=ef6bd2e2}}
Poland	Banned	Scheduled since March 2009{{cite|name=lotus-extracts-legal|type=web|author=Lotus-Extracts.com|year=2024|title=International legal status of blue lotus|anchor=e227a678}}
Latvia	Banned	Controlled substance{{cite|name=lotus-extracts-legal|type=web|author=Lotus-Extracts.com|year=2024|title=International legal status of blue lotus|anchor=13bf4e00}}
United Kingdom	Uncertain	Not specifically named in the Misuse of Drugs Act 1971. May fall under the Psychoactive Substances Act 2016 if sold for human consumption; personal possession generally considered legal{{flag|citation-needed}}
Canada	Legal	Not classified as a controlled substance by Health Canada. Legal for sale and possession; therapeutic claims require licensing{{flag|citation-needed}}
Germany	Legal	Permitted under general herbal product regulations{{flag|citation-needed}}
Netherlands	Legal	Available in smart shops; not scheduled as a controlled substance{{flag|citation-needed}}
Australia	Legal (uncontrolled)	Not listed as a controlled substance. Not approved by the TGA for human consumption or therapeutic use. Typically marketed for aromatic or ceremonial purposes{{cite|name=erowid-lotus-legal|type=web|author=Erowid.org|year=2016|title=Erowid Lotus Legal Status|anchor=326a9612}}

The plant's alkaloids are not controlled under international drug treaties. Apomorphine circulates as a regulated prescription pharmaceutical in jurisdictions where it is approved for Parkinson's disease, but this regulatory status pertains to the manufactured drug product, not to [[glossary:plant-material]] containing trace quantities. The primary legal risk for consumers in unregulated markets is the presence of [[glossary:synthetic]] [[substance_class:psychoactive/cannabinoid]] [[glossary:adulterant|adulterants]], which are controlled substances in most jurisdictions and can result in criminal [[glossary:liability]] regardless of the legal status of the plant itself.